Omid Veiseh

Establishment Labs Announces FDA Clearance of Motiva Flora SmoothSilk Tissue Expander

Retrieved on: 
Monday, October 16, 2023
Health, Medical Devices, Other Health, Artifact, Partnership, RFID, Earnings before interest, taxes, depreciation and amortization, Food, Google Images, Metal, Breast cancer, Inflammation, Breast, Radiology, Breast pain, Michelle Brunner, Heart, VMAT, Radiation, Motiva, University, FDA, Applied science, Rabbit, CT, Magnet, Environment, Luigi Cozzi, Safety, History, Medicine, Mouse, MRI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Establishment, Human, Woman, Diversified Specialty Institute Holdings, Inc., Patient, Surgeon, ESTA, Pharmaceutical industry, Medical imaging, Omid Veiseh

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander.
  • The Flora® SmoothSilk® Tissue Expander offers several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology.
  • By being magnet-free, Flora avoids the interference that magnets can cause during MRI and may improve the precision of radiation oncology treatment.
  • “This is an incredibly important day in the history of Establishment Labs, as the first of our implantable technologies has been approved by the FDA,” said Juan José Chacón-Quirós, Founder and Chief Executive Officer of Establishment Labs.

Rice Biotech Launch Pad introduces external advisory board

Retrieved on: 
Wednesday, October 4, 2023
Rice University, THOR, Neuroscience, Omid Veiseh, MBA, Geisinger Commonwealth School of Medicine, College of Engineering (KNUST), ARPA, Science, Harris Health System, Launch pad, Research, Health, Integration, Green Launching Pad, Massachusetts Institute of Technology, Pharmaceutical industry, Management

HOUSTON, Oct. 4, 2023 /PRNewswire/ -- Rice University today announced its external advisory board for the Rice Biotech Launch Pad, the new accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. Officially unveiled in September, the accelerator will help Rice researchers to advance internally discovered platform technologies from concept to clinical studies and commercialization.

Key Points: 
  • Group includes national and Houston-based leaders in science, academia, venture capital and investment banking
    HOUSTON, Oct. 4, 2023 /PRNewswire/ -- Rice University today announced its external advisory board for the Rice Biotech Launch Pad , the new accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • The external advisory board members are:
    Albert Cha, M.D., Ph.D., managing partner at Frazier Life Sciences , a health care investment firm.
  • I look forward to welcoming them to the Rice Biotech Launch Pad team as we continue to scale the capabilities of the accelerator."
  • We appreciate the commitment and dedication of the external advisory board members to help us realize the vision of the Biotech Launch Pad."

Rice Biotech Launch Pad accelerator aims to rapidly turn medical and health discoveries into cures

Retrieved on: 
Tuesday, September 12, 2023
Entrepreneurship, Rice University, University of Washington Department of Bioengineering, Business, Attention, College of Engineering (KNUST), ARPA, Jesse, DARPA, Texas Medical Center, Student, Engineering, Biological engineering, Jesse H. Jones Graduate School of Business, Faculty, Ecosystem, NIH, Pharmaceutical industry, Management, SYNOP, Cherukuri, Omid Veiseh, Rice

HOUSTON, Sept. 12, 2023 /PRNewswire/ -- Rice University today introduced the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. Supported by federal grants and philanthropic gifts, the new accelerator will bring together local researchers with a national network of industry executives, additional funding sources and about 15,000 square feet of accelerator space.

Key Points: 
  • HOUSTON, Sept. 12, 2023 /PRNewswire/ -- Rice University today introduced the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • The Rice Biotech Launch Pad is the university's first large-scale initiative designed to help advance internally discovered platform technologies from concept to clinical studies and commercialization.
  • "The Rice Biotech Launch Pad will ensure that our faculty and students have the skills, partnerships, tools and support to create technologies that can transform our city and the world," Rice President Reginald DesRoches said.
  • "More importantly, the accelerator will provide a pathway for these creations and discoveries to be turned into medical cures that significantly impact people's lives.